{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:37:02Z","timestamp":1793137022829,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40257-025-00928-w","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:50:35Z","timestamp":1740109835000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Dahyeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seanna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minka","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickoulet","family":"Babaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireya","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"928_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21:170\u20133. https:\/\/doi.org\/10.7861\/clinmed.2021-0257.","journal-title":"Clin Med"},{"key":"928_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W-H Boehncke","year":"2015","unstructured":"Boehncke W-H, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386:983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"key":"928_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases. J Am Acad Dermatol. 2017;76:377\u201390. https:\/\/doi.org\/10.1016\/j.jaad.2016.07.064.","journal-title":"J Am Acad Dermatol"},{"key":"928_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/BOR.0b013e3283031c99","volume":"20","author":"RS Azfar","year":"2008","unstructured":"Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20:416\u201322. https:\/\/doi.org\/10.1097\/BOR.0b013e3283031c99.","journal-title":"Curr Opin Rheumatol"},{"key":"928_CR5","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20:1475. https:\/\/doi.org\/10.3390\/ijms20061475.","journal-title":"Int J Mol Sci"},{"key":"928_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaci.2010.12.009","volume":"127","author":"A H\u00e4nsel","year":"2011","unstructured":"H\u00e4nsel A, G\u00fcnther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong T 17\/T 1 T-cell responses. J Allergy Clin Immunol. 2011;127:787-794.e9. https:\/\/doi.org\/10.1016\/j.jaci.2010.12.009.","journal-title":"J Allergy Clin Immunol"},{"key":"928_CR7","doi-asserted-by":"publisher","first-page":"32633","DOI":"10.1074\/jbc.M400642200","volume":"279","author":"T Banno","year":"2004","unstructured":"Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-\u03b1 (TNF\u03b1) in epidermal keratinocytes revealed using global transcriptional profiling. J Biol Chem. 2004;279:32633\u201342. https:\/\/doi.org\/10.1074\/jbc.M400642200.","journal-title":"J Biol Chem"},{"key":"928_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227\u201355. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120225.","journal-title":"Annu Rev Immunol"},{"key":"928_CR9","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"H-J Lee","year":"2023","unstructured":"Lee H-J, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24:13313. https:\/\/doi.org\/10.3390\/ijms241713313.","journal-title":"Int J Mol Sci"},{"key":"928_CR10","unstructured":"Ivanov R. International Clinical trial to evaluate efficacy and safety of multiple subcutaneous injections of BCD-085 in various doses in patients with moderate to severe plaque psoriasis. ClinicaltrialsGov 2021. https:\/\/clinicaltrials.gov\/study\/NCT02762994. Accessed 21 Aug 2024."},{"key":"928_CR11","unstructured":"China to conduct clinical trials of the Russian originator drug, netakimab. Biocad 2022. https:\/\/eng.biocad.ru\/posts\/china-to-conduct-clinical-trials-of-the-russian-originator-drug-netakimab. Accessed 12 Dec 2024."},{"key":"928_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/annrheumdis-2016-eular.1615","volume":"75","author":"E Chernyaeva","year":"2016","unstructured":"Chernyaeva E, Eremeeva A, Galustyan A, Ivanov R. FRI0010 Pharmacokinetics, safety and tolerance of BCD-085, a novel IL-17 inhibitor, based on the results of phase 1 clinical study in healthy volunteers. Ann Rheum Dis. 2016;75:429. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.1615.","journal-title":"Ann Rheum Dis"},{"key":"928_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","volume":"11","author":"L Puig","year":"2021","unstructured":"Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, et al. Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial. Dermatol Ther. 2021;11:1319\u201332. https:\/\/doi.org\/10.1007\/s13555-021-00554-4.","journal-title":"Dermatol Ther"},{"key":"928_CR14","unstructured":"An international multicenter, randomized, double-blind, placebo-controlled clinical study of efficacy and safety of two dosing regimens of BCD-085 (JSC BIOCAD, Russia) in patients with moderate to severe plaque psoriasis (BCD-085-7). ClinicaltrialsGov 2022. https:\/\/clinicaltrials.gov\/study\/NCT03390101. Accessed 21 Aug 2024."},{"key":"928_CR15","unstructured":"Study of the efficacy, safety, pharmacokinetics, and immunogenicity of netakimab in children with moderate to severe plaque psoriasis (PLANETA-KIDS). ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06640517. Accessed 12 Dec 2024."},{"key":"928_CR16","unstructured":"Clinical study of efficacy and safety of bcd-085 (monoclonal anti-IL-17 antibody) in psoriatic arthritis (PATERA). ClinicaltrialsGov 2021. https:\/\/clinicaltrials.gov\/study\/NCT03598751. Accessed 21 Aug 2024."},{"key":"928_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.47360\/1995-4484-2020-480-488","volume":"58","author":"TV Korotaeva","year":"2020","unstructured":"Korotaeva TV, Mazurov VI, Lila AM, Gaydukova IZ, Bakulev AL, Samtsov AV, et al. Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study. Rheumatol Sci Pract. 2020;58:480\u20138. https:\/\/doi.org\/10.47360\/1995-4484-2020-480-488.","journal-title":"Rheumatol Sci Pract"},{"key":"928_CR18","unstructured":"Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT03463187?intr=SHR-1314. Accessed 5 Sept 2024."},{"key":"928_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","volume":"87","author":"C Zhang","year":"2022","unstructured":"Zhang C, Yan K, Diao Q, Guo Q, Jin H, Yang S, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022;87:95\u2013102. https:\/\/doi.org\/10.1016\/j.jaad.2022.01.005.","journal-title":"J Am Acad Dermatol"},{"key":"928_CR20","unstructured":"Efficacy, safety and PK of SHR-1314 in patients with moderate-to-severe plaque psoriasis. ClinicaltrialsGov 2021. https:\/\/clinicaltrials.gov\/study\/NCT04839016. Accessed 13 Dec 2024."},{"key":"928_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031","author":"K Yan","year":"2024","unstructured":"Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, et al. Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2024. https:\/\/doi.org\/10.1016\/j.jaad.2024.09.031.","journal-title":"J Am Acad Dermatol"},{"key":"928_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","volume":"84","author":"SJ Keam","year":"2024","unstructured":"Keam SJ. Vunakizumab: first approval. Drugs. 2024;84:1481\u20135. https:\/\/doi.org\/10.1007\/s40265-024-02110-8.","journal-title":"Drugs"},{"key":"928_CR23","unstructured":"Phase IV study: vunakizumab efficacy and safety in moderate-to-severe plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06696417. Accessed 13 Dec 2024."},{"key":"928_CR24","unstructured":"Study of the effectiveness and safety of SHR-1314 for psoriatic arthritis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT05055934. Accessed 13 Dec 2024."},{"key":"928_CR25","unstructured":"Zou H, Wan W, Xue Y, Sun L, Zhang N, Chen H, et al. Vunakizumab in patients with active psoriatic arthritis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 study, 2024."},{"key":"928_CR26","unstructured":"A study of the efficacy and safety of SHR-1314 for adult active psoriatic arthritis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06640257. Accessed 13 Dec 2024."},{"key":"928_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039067","volume":"10","author":"W Dong","year":"2020","unstructured":"Dong W, Nie X, Wang J, Xia L, Cai L, Wang Q, et al. Randomised, double-blind, multicentre, phase I\/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open. 2020;10: e039067. https:\/\/doi.org\/10.1136\/bmjopen-2020-039067.","journal-title":"BMJ Open"},{"key":"928_CR28","unstructured":"Products pipelines. Genrix Bio n.d. http:\/\/www.genrixbio.com\/#\/science?classId=class3. Accessed 13 Dec 2024."},{"key":"928_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/bjd\/ljae062","volume":"191","author":"L Cai","year":"2024","unstructured":"Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, et al. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2024;191:336\u201343. https:\/\/doi.org\/10.1093\/bjd\/ljae062.","journal-title":"Br J Dermatol"},{"key":"928_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jcph.6129","volume":"65","author":"Q Meng","year":"2025","unstructured":"Meng Q, Wang W, Zhang L, Shi H, Liu H, Zheng Q, et al. Population pharmacokinetics of xeligekimab: an anti-IL-17A monoclonal antibody, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2025;65:53\u201365. https:\/\/doi.org\/10.1002\/jcph.6129.","journal-title":"J Clin Pharmacol"},{"key":"928_CR31","doi-asserted-by":"publisher","unstructured":"Blair HA. Xeligekimab: first approval 2024:201528 Bytes. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.27320757.V1.","DOI":"10.6084\/M9.FIGSHARE.27320757.V1"},{"key":"928_CR32","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s13555-022-00880-1","volume":"13","author":"C Jiang","year":"2023","unstructured":"Jiang C, Zhou H, Zhang W, Xia Y, Li B, Ni X, et al. Efficacy, safety and pharmacokinetics of IL-17 monoclonal antibody injection (AK111) in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled phase Ib multidose escalation clinical study. Dermatol Ther. 2023;13:555\u201367. https:\/\/doi.org\/10.1007\/s13555-022-00880-1.","journal-title":"Dermatol Ther"},{"key":"928_CR33","unstructured":"A phase 2 study of efficacy and safety of AK111 in subjects with moderate-to-severe psoriasis. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT05096364. Accessed 13 Dec 2024."},{"key":"928_CR34","unstructured":"To evaluate the efficacy and safety of AK111 injection in the treatment of moderate to severe plaque psoriasis. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT06061471. Accessed 13 Dec 2024."},{"key":"928_CR35","unstructured":"A study to evaluate the efficacy and safety of AK111 in subjects with moderate to severe plaque psoriasis. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT06066125. Accessed 13 Dec 2024."},{"key":"928_CR36","unstructured":"Akeso released complete phase 3 data for gumokimab (AK111, IL-17) in moderate to severe plaque psoriasis. Akesobio 2024. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/241028\/. Accessed 13 Dec 2024."},{"key":"928_CR37","unstructured":"A study of injection HB0017 in adult healthy volunteers. ClinicalTrials.gov; n.d."},{"key":"928_CR38","unstructured":"A study of injection HB0017 in adult healthy volunteers. ClinicaltrialsGov 2021. https:\/\/clinicaltrials.gov\/study\/NCT04505033. Accessed 13 Dec 2024."},{"key":"928_CR39","unstructured":"A study of HB0017 in patients with moderate to severe plaque psoriasis. ClinicaltrialsGov 2022. https:\/\/clinicaltrials.gov\/study\/NCT05442788. Accessed 13 Dec 2024."},{"key":"928_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/bjd\/ljad315","volume":"190","author":"C Jiang","year":"2023","unstructured":"Jiang C, Du Y, Liu X, Wang J, Ge C, Xu J, et al. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2023;190:28\u201336. https:\/\/doi.org\/10.1093\/bjd\/ljad315.","journal-title":"Br J Dermatol"},{"key":"928_CR41","unstructured":"A study to evaluate the efficacy and safety of HB0017 in patients with moderate to severe plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT05531682. Accessed 13 Dec 2024."},{"key":"928_CR42","unstructured":"A phase 2 study to explore the efficacy and safety of HB0017 longer dose interval in psoriasis patients (HB0017). ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06592274. Accessed 13 Dec 2024."},{"key":"928_CR43","unstructured":"Study of efficacy and safety of HB0017 in patients with moderate to severe plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06477237. Accessed 13 Dec 2024."},{"key":"928_CR44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/jdv.17071","volume":"35","author":"M Kaul","year":"2021","unstructured":"Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, et al. First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2021;35:1143\u201351. https:\/\/doi.org\/10.1111\/jdv.17071.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"928_CR45","unstructured":"Single and multiple dose escalation study to assess the safety and tolerability of CJM112 in psoriasis. ClinicaltrialsGov 2020. https:\/\/clinicaltrials.gov\/study\/NCT01828086. Accessed 16 Dec 2024."},{"key":"928_CR46","unstructured":"Cai L, Mu Z, Tao X, Zhang L, Zhang C, Li Y, et al. A phase Ib\/II randomized, double-blind, placebo-controlled study of novel anti-IL-17A monoclonal antibody JS005 in patients with moderate to severe psoriasis [abstract]. Arthritis Rheumatol. 2023;75(suppl 9). https:\/\/acrabstracts.org\/abstract\/a-phase-ib-ii-randomized-double-blind-placebo-controlled-study-of-novel-anti-il-17a-monoclonal-antibody-js005-in-patients-with-moderate-to-severe-psoriasis\/."},{"key":"928_CR47","unstructured":"Safety, tolerance, efficacy and pharmacokinetics of JS005 multiple dosing. ClinicaltrialsGov 2022. https:\/\/clinicaltrials.gov\/study\/NCT05344248. Accessed 17 Dec 2024."},{"key":"928_CR48","unstructured":"A clinical study to evaluate the efficacy and safety of subcutaneous JS005 injection in the treatment of adults with moderate to severe chronic plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT05975268. Accessed 17 Dec 2024."},{"key":"928_CR49","unstructured":"A phase III study of recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with PsO. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06299982. Accessed 17 Dec 2024."},{"key":"928_CR50","unstructured":"A study to evaluate the efficacy and safety of LZM012 (psoriasis). ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT06110676. Accessed 17 Dec 2024."},{"key":"928_CR51","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/exd.14861","volume":"32","author":"R Sinclair","year":"2023","unstructured":"Sinclair R, Sharifeh S, Thackwray S, Lickliter J, Wu J, Li J, et al. Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: results of a randomised, double-blind, placebo-controlled Phase Ib study. Exp Dermatol. 2023;32:1538\u201345. https:\/\/doi.org\/10.1111\/exd.14861.","journal-title":"Exp Dermatol"},{"key":"928_CR52","unstructured":"A phase 2 study of ZL-1102 in patients with chronic plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06380907. Accessed 17 Dec 2024."},{"key":"928_CR53","doi-asserted-by":"publisher","first-page":"2209920","DOI":"10.1080\/19420862.2023.2209920","volume":"15","author":"S Klint","year":"2023","unstructured":"Klint S, Feldwisch J, Gudmundsdotter L, Dillner Bergstedt K, Gunneriusson E, H\u00f6id\u00e9n Guthenberg I, et al. Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. MAbs. 2023;15:2209920. https:\/\/doi.org\/10.1080\/19420862.2023.2209920.","journal-title":"MAbs"},{"key":"928_CR54","unstructured":"Valasseri S. A study to investigate the safety, tolerability and pharmacokinetics of ABY-035. ClinicaltrialsGov 2018. https:\/\/clinicaltrials.gov\/study\/NCT02690142. Accessed 13 Dec 2024."},{"key":"928_CR55","unstructured":"Gerdes S. A study to evaluate ABY-035 in subjects with moderate-to-severe plaque psoriasis (AFFIRM-35). ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT03591887. Accessed 13 Dec 2024."},{"key":"928_CR56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/bjd\/ljad186","volume":"189","author":"S Gerdes","year":"2023","unstructured":"Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, et al. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol. 2023;189:381\u201391. https:\/\/doi.org\/10.1093\/bjd\/ljad186.","journal-title":"Br J Dermatol"},{"key":"928_CR57","unstructured":"Pipeline. Affibody Med AB n.d. https:\/\/www.affibody.se\/research-development\/our-pipeline\/. Accessed 13 Dec 2024."},{"key":"928_CR58","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/annrheumdis-2022-eular.536","volume":"81","author":"F Behrens","year":"2022","unstructured":"Behrens F, Taylor PC, Wetzel D, Brun NC, Brandt-Juergens J, Drescher E, et al. OP0258 izokibep (aby-035) in patients with active psoriatic arthritis\u201416-week results from a phase 2 study. Ann Rheum Dis. 2022;81:170\u20131. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.536.","journal-title":"Ann Rheum Dis"},{"key":"928_CR59","doi-asserted-by":"publisher","unstructured":"Mease PJ, Behrens F, Kivitz A, Drescher E, Klimiuk PA, Sofen H, et al. LBA0005 efficacy and safety of izokibep, a novel IL-17A inhibitor, in patients with active psoriatic arthritis: week 16 results from a randomized, double-blind, placebo-controlled, multicenter phase 2b\/3 study. Sci Abstr. BMJ Publishing Group Ltd and European League Against Rheumatism; 2024, p. 235\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.LBA85.","DOI":"10.1136\/annrheumdis-2024-eular.LBA85"},{"key":"928_CR60","unstructured":"ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results. Acelyrin 2024. https:\/\/investors.acelyrin.com\/news-releases\/news-release-details\/acelyrin-inc-announces-positive-phase-3-data-izokibep. Accessed 12 Dec 2024."},{"key":"928_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jaad.2019.03.056","volume":"81","author":"D Svecova","year":"2019","unstructured":"Svecova D, Lubell MW, Casset-Semanaz F, Mackenzie H, Grenningloh R, Krueger JG. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti\u2013interleukin 17A\/F nanobody, in moderate-to-severe psoriasis. J Am Acad Dermatol. 2019;81:196\u2013203. https:\/\/doi.org\/10.1016\/j.jaad.2019.03.056.","journal-title":"J Am Acad Dermatol"},{"key":"928_CR62","unstructured":"Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A\/F nanobody) in psoriasis subjects. ClinicaltrialsGov 2017. https:\/\/clinicaltrials.gov\/study\/NCT02156466. Accessed 15 Dec 2024."},{"key":"928_CR63","unstructured":"A phase 2b study of the efficacy, safety, and tolerability of M1095 (sonelokimab) in subjects with moderate to severe psoriasis 2021. https:\/\/clinicaltrials.gov\/study\/NCT03384745?term=NCT03384745. Accessed 21 Augu 2024."},{"key":"928_CR64","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"KA Papp","year":"2021","unstructured":"Papp KA, Weinberg MA, Morris A, Reich K. IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021;397:1564\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(21)00440-2.","journal-title":"Lancet"},{"key":"928_CR65","unstructured":"Pipeline. Moonlake TX n.d. https:\/\/moonlaketx.com\/pipeline\/. Accessed 29 Sept 2024."},{"key":"928_CR66","unstructured":"Evaluation of sonelokimab for the treatment of patients with active psoriatic arthritis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT05640245. Accessed 15 Dec 2024."},{"key":"928_CR67","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/annrheumdis-2024-eular.1295","volume":"83","author":"IB Mc Innes","year":"2024","unstructured":"Mc Innes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, et al. OP0195 efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody\u00ae, in patients with active psoriatic arthritis (PsA): results from the global, randomized, double-blind, placebo-controlled phase 2 argo trial. Ann Rheum Dis. 2024;83:154. https:\/\/doi.org\/10.1136\/annrheumdis-2024-eular.1295.","journal-title":"Ann Rheum Dis"},{"key":"928_CR68","unstructured":"Evaluation of sonelokimab in patients with active psoriatic arthritis naive to biologic disease-modifying antirheumatic drug (IZAR-1). ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06641076. Accessed 15 Dec 2024."},{"key":"928_CR69","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/cpt.3185","volume":"115","author":"A Datta-Mannan","year":"2024","unstructured":"Datta-Mannan A, Regev A, Coutant DE, Dropsey AJ, Foster J, Jones S, et al. Safety, tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): a phase I randomized placebo-controlled study. Clin Pharmacol Ther. 2024;115:1152\u201361. https:\/\/doi.org\/10.1002\/cpt.3185.","journal-title":"Clin Pharmacol Ther"},{"key":"928_CR70","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.medidd.2020.100075","volume":"9","author":"FD Makurvet","year":"2021","unstructured":"Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075. https:\/\/doi.org\/10.1016\/j.medidd.2020.100075.","journal-title":"Med Drug Discov"},{"key":"928_CR71","unstructured":"Pipeline. DICE Ther n.d. https:\/\/www.dicetherapeutics.com\/pipeline\/. Accessed 17 Sept 2024."},{"key":"928_CR72","unstructured":"DICE therapeutics announces positive topline data from phase 1 clinical trial of lead oral IL-17 antagonist, DC-806, for psoriasis. GlobeNewswire n.d. https:\/\/www.globenewswire.com\/news-release\/2022\/10\/11\/2531642\/0\/en\/DICE-Therapeutics-Announces-Positive-Topline-Data-from-Phase-1-Clinical-Trial-of-Lead-Oral-IL-17-Antagonist-DC-806-for-Psoriasis.html. Accessed 17 Sept 2024."},{"key":"928_CR73","unstructured":"A study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis (illuminate). ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT05896527. Accessed 15 Dec 2024."},{"key":"928_CR74","unstructured":"A study of LY4100511 (Dice 853) in adult participants with moderate-to-severe plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06602219. Accessed 16 Dec 2024."},{"key":"928_CR75","unstructured":"A single and multiple ascending-dose trial of LEO 153339 in healthy adults. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT04883333?intr=LEO%20153339. Accessed 17 Dec 2024."},{"key":"928_CR76","unstructured":"Comparative study of CMAB015 and secukinumab for patients with moderate to severe plaque psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06398652. Accessed 11 Dec 2024."},{"key":"928_CR77","unstructured":"Phase I randomized, open-label, parallel-controlled, pharmacokinetic and safety study of BR201 injection versus cosentyx in healthy male subjects. ClinicaltrialsGov 2023. https:\/\/clinicaltrials.gov\/study\/NCT06126718. Accessed 11 Dec 2024."},{"key":"928_CR78","unstructured":"Assessment on efficacy and safety of BAT2306 and Cosentyx\u00ae in plaque psoriasis patients. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06630559. Accessed 11 Dec 2024."},{"key":"928_CR79","unstructured":"A study to compare efficacy and safety of CT-P55 and Cosentyx in patients with moderate to severe psoriasis. ClinicaltrialsGov 2024. https:\/\/clinicaltrials.gov\/study\/NCT06630559. Accessed 11 Dec 2024."},{"key":"928_CR80","unstructured":"Luye Pharma acquires Boan with strategic plans in biopharmaceuticals further strengthening product pipeline and accelerating global business growth. Luye Pharma 2019. https:\/\/www.luye.cn\/lvye_en\/view.php?id=1782. Accessed 11 Dec 2024."},{"key":"928_CR81","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.adengl.2019.12.016","volume":"112","author":"B Pinilla Mart\u00edn","year":"2021","unstructured":"Pinilla Mart\u00edn B, S\u00e1nchez Vel\u00e1zquez A, Vico Alonso C, Rivera DR. Switching from one anti-IL-17 antibody to another: on trying again or changing the target. Actas Dermo-Sifiliogr\u00e1ficas Engl Ed. 2021;112:473\u20135. https:\/\/doi.org\/10.1016\/j.adengl.2019.12.016.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas Engl Ed"},{"key":"928_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15772","author":"M Tichy","year":"2022","unstructured":"Tichy M, Kojanova M, Velackova B, Dolezal T, Gkalpakiotis S, Cetkovska P, et al. Efficacy of switches within the class of IL -17 inhibitors: an analysis of data from the Czech nationwide registry of psoriatic patients receiving biological\/targeted therapy (BIOREP). Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15772.","journal-title":"Dermatol Ther"},{"key":"928_CR83","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311:421\u20134. https:\/\/doi.org\/10.1007\/s00403-019-01907-y.","journal-title":"Arch Dermatol Res"},{"key":"928_CR84","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","volume":"84","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, Barenbrug L, Hannink G, Seyger MMB, De Jong EMGJ, Van Den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84:565\u201378. https:\/\/doi.org\/10.1007\/s40265-024-02028-1.","journal-title":"Drugs"},{"key":"928_CR85","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2147\/PPA.S463354","volume":"18","author":"J Myers","year":"2024","unstructured":"Myers J, Van Dam J, Imran M, Hashim M, Dhalla A. Preference for a novel oral alternative to parenterally administered medications. Patient Prefer Adherence. 2024;18:1547\u201362. https:\/\/doi.org\/10.2147\/PPA.S463354.","journal-title":"Patient Prefer Adherence"},{"key":"928_CR86","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/DDDT.S470619","volume":"18","author":"F Yao","year":"2024","unstructured":"Yao F, Wang C, Ding J, Zhang Q, Zheng L, Zhang Q, et al. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of CMAB015, a candidate secukinumab biosimilar, with its reference product Cosentyx\u00ae in healthy Chinese male subjects. Drug Des Devel Ther. 2024;18:3891\u2013901. https:\/\/doi.org\/10.2147\/DDDT.S470619.","journal-title":"Drug Des Devel Ther"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00928-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00928-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:57:00Z","timestamp":1747454220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00928-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00928-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"3 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None was received.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Aristea Therapeutics, Bausch Health, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Codex Labs, Dermavant, DermTech, Dr. Reddy's Laboratories, Eli Lilly, EPI Health, Galderma, Incyte, Janssen, LEO Pharma, Mindera, Novartis, Pfizer, Regeneron, Samsung Bioepis, Sanofi Genzyme, Solius, Sun Pharmaceutical, UCB, and Zerigo Health. No conflicts of interest for Dahyeon Kim, Seanna Yang, Minka Gill, Nickoulet Babaei, and Mireya Cervantes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All listed authors had substantial contributions to the design of the work and to its review, approve of its final version, and agree to be accountable for all aspects. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}